Novartis AG is highlighting the advantages of its new chronic spontaneous urticaria (CSU) treatment ligelizumab over the current standard of care Xolair which the firm markets with Roche for the distressing condition that causes red, itchy and sometimes painful hives on the skin.
Like Xolair (omalizumab), ligelizumab is an immunoglobulin E inhibitor but Novartis has pointed to new mechanistic data published in the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
